Fulgent Genetics, Inc. (FLGT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Fulgent Genetics, Inc.'s filing signal turned positive.

Fulgent Genetics, Inc. operates as a technology-based company with a dual focus on laboratory services and therapeutic development. Its laboratory services segment offers comprehensive anatomic pathology and precision diagnostics, including next-generation sequencing, for a wide range of diseases and biopharma research. The therapeutic development business, Fulgent Pharma, is focused on developing cancer treatments using a novel nanoencapsulation and targeted therapy platform. Founded in 2011, the company emphasizes flexibility and affordability in its diagnostic offerings, aiming to become a fully integrated precision medicine company. Fulgent Genetics serves insurance, institutional, and direct patient payors, with one customer accounting for 22% of its revenue in 2025.

Revenue is primarily driven by its laboratory services, which include precision diagnostics and anatomic pathology testing, as well as BioPharma services. The therapeutic development segment contributes revenue through licensed technologies and manufacturing agreements.